Cipla Health to acquire Endura Mass from Medinnbelle Hervalcare

Pharma major Cipla Ltd on Thursday said its arm Cipla Health Ltd has signed definitive agreements to acquire nutritional supplement brand Endura Mass from Medinnbelle Herbalcare for an undisclosed sum. PTI) Pharma major Cipla Ltd on Thursday said its arm Cipla Health Ltd has signed definitive agreements to acquire nutritional supplement brand Endura Mass from Medinnbelle Herbalcare for an undisclosed sum. The acquisition is in line with Cipla's strategic imperative to augment its wellness portfolio for bringing about a shift from an illness to a wellness mindset. It will include Endura and all other associated trademarks, the company said in a regulatory filing "With this strategic acquisition, we will be expanding our portfolio into a new category of weight gain, thereby catering to a very specific nutritional need for a set of our consumers," Cipla Health Ltd (CHL) CEO Shivam Puri said. He further said, "The addition of Endura & Endura Mass to our portfolio hence perfectly complements our existing offerings across all key OTC/wellness categories and would hence help us offer an even more comprehensive solution to all key consumer needs." The acquisition is subject to completion of certain closing conditions and CHL would immediately initiate distribution and marketing of the said products pending the closure of the proposed acquisition, the filing added. Cipla said CHL, through this acquisition, is well positioned to further build and develop the nutrition supplement category through its strong existing offline and online distribution channels. It has 12 brands within the portfolio. PTI RKL HVA

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!